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Abstract It is well established that adenovirus E1B-55K pro-
tein functions as an inhibitor of the tumor suppressor protein
p53 by binding and inactivating p53 as a transcriptional activa-
tor protein. Here we show that the adenovirus 2 E1B-55K pro-
tein also blocks p53 as a transcriptional repressor protein of the
survivin and the MAP4 promoters. The repression is dependent
on the ability of E1B-55K to bind to p53 and is enhanced by
coexpression of the adenovirus E4orf6 protein. Overexpression
of the transcriptional corepressor protein Sin3A partially re-
lieves the inhibitory e¡ect of E1B-55K, suggesting that E1B-
55K blocks p53 functions by interfering with the Sin3 complex.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The adenovirus (Ad) E1B-55K protein is a multifunctional
phosphoprotein that serves several critical functions during
lytic virus growth (reviewed in [1]). Since the discovery of
E1B-55K as a binding partner to the human tumor suppressor
protein p53 [2], a main focus in E1B-55K research has been
on the functional consequence of this interaction on di¡erent
p53-regulated processes. It is well documented that E1B-55K
binding to the amino-terminal transactivation domain of p53
functionally inactivates p53 as a transcription activator of
di¡erent p53-dependent promoters [3,4].
The p53 protein is a nuclear transcription factor that is
latent in normal cells, but becomes activated by a variety of
stress signals. Following induction p53 upregulates a set of
genes, such as p21, GADD45, cyclin G and Bax, that can
promote cell death or growth arrest (reviewed in [5]). More
recently, p53 has been shown to repress transcription of a
number of genes, including bcl-2, MAP4 and survivin, all of
which have been implicated as proteins opposing apoptosis
[6,7].
Compared to the wealth of knowledge about p53 as a tran-
scriptional activator protein, limited data are available on
how p53 inhibits transcription. The recent observation that
p53 associates with the Sin3 corepressor complex may be of
signi¢cance in order to explain how p53 inhibits transcription
[8]. The Sin3 complex is a transcriptional repressor complex,
consisting of the Sin3A, HDAC1, and HDAC2 proteins,
which regulate chromatin structure by histone deacetylation
[9]. The interaction between p53 and Sin3A targets histone
deacetylases to the promoter of a p53-repressed gene, thereby
creating a chromatin environment that is unfavorable for
transcription initiation [8].
We have previously shown that the adenovirus E1B-55K
protein interacts with HDAC1 and Sin3A [10]. The novel
¢ndings on p53-mediated transcription repression by recruit-
ment of the Sin3 complex prompted us to test the possibility
that E1B-55K might interfere with p53-mediated repression of
transcription through the Sin3 complex.
As a model substrate for a repressed promoter, we selected
the human survivin promoter. Recent studies have shown that
survivin transcription can be repressed by p53 through re-
cruitment of the Sin3 protein and by changes in chromatin
structure that a¡ect promoter accessibility [7,11].
Here we report that the Ad2 E1B-55K protein can relieve
p53-mediated transcriptional repression of the survivin and
the MAP4 promoters. Furthermore, we show that the e¡ect
is dependent on the ability of E1B-55K to bind to p53. The
capacity of the E1B-55K protein to relieve p53-mediated tran-
scriptional repression of the survivin promoter was enhanced
by coexpression of the adenovirus E4orf6 protein. We also
show that overexpression of the Sin3A protein partially op-
posed the e¡ect of E1B-55K on the survivin promoter, sug-
gesting that E1B-55K may accomplish this by interfering with
the Sin3 complex.
2. Materials and methods
2.1. Plasmids
Plasmid maps and sequences are available on request. Plasmid
pCMVE1B-55K was generated by cleavage of pBSE1B-55K [10]
with HincII and ligation of BamHI linkers to the 3P ends of the
E1B-55K sequence. The E1B-55K sequence was subsequently recloned
into the pCMVNeoBam plasmid [12] as a BamHI/BamHI fragment.
Plasmid pCH110, encoding L-galactosidase, was purchased from
Amersham Pharmacia Biotech. The point mutations inserted into
plasmids pCMVE1B-55K, pCGp53 and pGEXp53 were generated
using the Quick Change Site-Directed Mutagenesis kit (Stratagene).
The MAP4-Luc plasmid was kindly provided by Dr. Maureen Mur-
phy. Plasmids SpII-Luc, pCMVE4orf6, pcDNAmSin3A, pCGp53(wt)
and cyclin G-Luc have been described previously [7,13^16].
2.2. Transfections and luciferase assay
H1299 cells were seeded in 35 mm plates at 1.5U105 cells per plate
and allowed to grow overnight. Transfections were done in duplicate
in several independent experiments, using the FuGene6 (Roche) trans-
fection reagent according to the manufacturer’s protocol. The amount
of DNA used is speci¢ed in the ¢gure legends, except for pCH110,
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which was constantly used at 1 Wg per transfection. After 36 h of
incubation, luciferase assay and L-galactosidase assay were performed
using the Luciferase Assay System (Promega) or Galacto-Star System
(Applied Biosystems), respectively. The reactions were analyzed on
Luminoscan (Labsystems). Luciferase activity was normalized to total
protein level and to L-galactosidase activity.
2.3. In vitro and in vivo binding assays
H1299 cells, transfected with 2 Wg of pCMVE1B-55K plasmids,
were lysed 36 h after transfection in bu¡er J (20 mM Tris^HCl pH
7.5, 100 mM NaCl, 10% glycerol, 1 mM EDTA, 0.1% NP40) and
passed through a 21G needle. Equal amounts of the lysates were
precleared by incubation with glutathione S-transferase (GST) bound
to glutathione Sepharose beads. Approximately 1 Wg of GST-p53 or
GST-p53P27Y proteins bound to glutathione Sepharose beads were
incubated with 500 Wg of precleared H1299 lysates for 1 h. The beads
were washed four times with bu¡er J and eluted proteins were re-
solved on 10% sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE). Western blotting was performed using an anti-
E1B-55K (2A6) [17] or an anti-p53 (mAb421) [15] antibody. Coim-
munoprecipitations with an anti-Sin3A antibody and puri¢cation of
GST fusion proteins were done as described previously [10].
3. Results
3.1. E1B-55K relieves p53-mediated transcriptional repression
of the survivin promoter
It is well established that E1B-55K binds and inhibits p53
as a transcriptional activator protein [4]. Here we tested the
hypothesis that E1B-55K interaction with p53 also blocks p53
as a transcriptional repressor protein. For this experiment,
H1299 cells were transfected with a survivin luciferase report-
er construct and plasmids encoding the p53 and E1B-55K
proteins. In agreement with previous results [7], the wild-
type p53 protein repressed survivin promoter activity
(Fig. 1A, lane 2). However, cotransfection of increasing
amounts of a plasmid encoding the E1B-55K protein relieved
the p53-mediated repression, in a concentration-dependent
manner (Fig. 1A, lanes 4 and 6). The same amounts of the
E1B-55K plasmid used in the survivin promoter assay were
also able to repress p53-activated transcription of the cyclin G
promoter (Fig. 1B, lanes 4 and 6). This result is important as
it shows that under the same experimental conditions, E1B-
55K blocks p53 as both a repressor and activator of tran-
scription.
Collectively our results show that E1B-55K, in addition to
blocking p53 as a transcriptional activator protein, can also
relieve p53-mediated transcriptional repression of the survivin
promoter.
3.2. E1B-55K binding to p53 is necessary to block p53 as a
transcriptional repressor protein
To show that the E1B-55K e¡ect is dependent on binding
to p53, we tested the p53 point mutant protein, p53(P27Y),
which has a reduced binding capacity to the E1B-55K protein
[18]. As shown in Fig. 1A, lane 3, the p53(P27Y) protein
showed similar repressor activity as wild-type p53 on the sur-
vivin promoter. However, coexpression of E1B-55K did not
signi¢cantly relieve the repressive e¡ect of p53(P27Y) (lanes 5
and 7), suggesting that E1B-55K has to make physical contact
with p53 to inactivate it as a transcriptional repressor protein.
A mutation changing the conserved histidine 260 to alanine
has been shown to drastically reduce the Ad5 E1B-55K pro-
tein binding to p53 [19]. Therefore, we created the correspond-
ing point mutation in Ad2 E1B-55K (mutant E1B-
55K(H259A)). Another point mutant, E1B-55K(Y443A),
was used as a control, to show the speci¢city of the H259A
mutation. The results from H1299 transfected cells showed
that the E1B55K(H259A) protein was impaired in its capacity
to relieve p53-mediated repression of the survivin promoter
(Fig. 2A, compare lanes 3 and 4). However, the C-terminal
point mutant Y443A was essentially as e⁄cient as the wild-
type E1B-55K protein in inactivating p53 as transcriptional
repressor protein (Fig. 2A, lane 5). Interestingly, the same
E1B-55K point mutants showed a di¡erence in activity
when tested on the p53-activated cyclin G promoter. As
shown in Fig. 2B, E1B-55K(H259A) had a reduced capacity
to block p53-activated transcription compared to wild-type
E1B-55K, whereas mutant Y443A was essentially as e¡ective
as the wild-type E1B-55K protein (Fig. 2B, lane 4). Thus, it is
noteworthy that the e¡ect of the E1B-55K(H259A) protein
was more dramatic on the survivin promoter compared to
the cyclin G promoter. We also tested if E1B-55K can inter-
fere with another p53 repressed promoter. To that end, we
used the MAP4 promoter, which has been shown to be re-
pressed by p53 expression [8]. Similarly to survivin promoter,
the E1B-55K expression opposed p53-mediated repression of
the MAP4 promoter in a p53-binding-dependent manner
(Fig. 2C). All E1B-55K proteins were expressed at compara-
ble levels (Fig. 2D).
To study the binding capacity of E1B-55K(H259A) to p53,
we incubated puri¢ed recombinant GST-p53 or GST-
p53(P27Y) proteins with cell lysates prepared from H1299
cells transfected with E1B-55K encoding plasmids. As shown
in Fig. 3A, the E1B-55K(wt) protein showed a strong inter-
action with GST-p53 (lane 2). In contrast, the E1B-
Fig. 1. E1B-55K relieves p53-mediated transcriptional repression of
the survivin promoter. A: H1299 cells transfected with 1 Wg of the
survivin promoter construct SpII, 10 ng p53(wt) or p53(P27Y) and
increasing amounts (10^50 ng) of E1B-55K(wt) plasmids. The activ-
ity of SpII in the absence of p53 was taken as 100%. B: H1299 cells
transfected with 100 ng of the cyclin G promoter construct and the
same amounts of plasmids encoding p53 and E1B-55K as in A. The
activity of the cyclin G luciferase in the presence of p53 or
p53(P27Y) was taken as 100%.
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55K(H259A) protein did not bind to GST-p53 under our ex-
perimental conditions (compare lanes 2 and 5). The speci¢city
of the interactions was con¢rmed with GST-p53(P27Y) pro-
tein, which did not show detectable binding to E1B-55K(wt)
or E1B-55K(H259A) (Fig. 3A, lanes 3 and 6). This result is in
agreement with our ¢nding that E1B-55K(H259A) was essen-
tially non-functional as an inhibitor of p53-mediated repres-
sion of survivin and MAP4 promoter activity (Fig. 2A,C).
3.3. Sin3A overexpression partially abolishes the inhibitory
e¡ect of E1B-55K on p53-mediated repression of the
survivin promoter
Previous studies have shown that p53 binds the Sin3A pro-
tein [8]. In addition, we have shown that E1B-55K also inter-
acts with the Sin3A protein [10]. To test if the E1B-
55K(H259A) mutant protein was able bind the Sin3A protein,
H1299 cells were transfected with the E1B-55K(wt) and the
E1B-55K(H259A) constructs. Cell lysates were immunopreci-
pitated with an anti-Sin3A antibody and interacting E1B-55K
proteins were detected in a Western blot using an antibody
directed against E1B-55K. As shown in Fig. 3B, the endoge-
nous Sin3A protein interacted e⁄ciently with both the E1B-
55K(wt) and the E1B-55K(H259A) proteins (lanes 5 and 6).
The speci¢city of the interactions was con¢rmed by immuno-
precipitating the same lysates with an anti-Gal4 antibody,
which did not coimmunoprecipitate the E1B-55K proteins
(lanes 8 and 9).
Fig. 2. E1B-55K binding to p53 is a prerequisite to relieve the p53-
mediated repression of survivin and MAP4 promoter activity.
A: H1299 cells were transfected with 1 Wg of the survivin promoter
construct SpII, 10 ng of p53 and 50 ng of E1B-55K encoding plas-
mids. The activity of SpII in the absence of p53 was taken as 100%.
B: H1299 cells transfected with 100 ng of the cyclin G promoter
construct and the same amounts of p53 and E1B-55K encoding
plasmids as in A. The activity of the cyclin G promoter in the pres-
ence of p53 was taken as 100%. C: H1299 cells transfected with
1 Wg of MAP4-Luc, 20 ng of p53 or p53P27Y and 100 ng of E1B-
55K or E1B55K(H259A) encoding plasmids. The activity of MAP4-
Luc in the absence of p53 was taken as 100%. D: Western blot
showing the expression of E1B-55K proteins, detected with an anti-
E1B-55K antibody.
Fig. 3. E1B-55K(H259A) is de¢cient in p53 binding, but not binding
to the Sin3A protein. A: H1299 cells expressing E1B-55K(wt) or
E1B-55K(H259A) proteins were lysed and incubated with puri¢ed
GST-p53 (lanes 2 and 5) or GST-p53(P27Y) (lanes 3 and 6). Bound
proteins were resolved by 10% SDS^PAGE and Western blot analy-
ses performed with anti-E1B-55K or anti-p53 antibodies. B: H1299
cells transfected with E1B-55K(wt) or E1B-55K(H259A) encoding
plasmids were lysed and coimmunoprecipitations were done using
an anti-Sin3A (lanes 4^6) or an anti-Gal4 antibody (lanes 7^9). In-
puts (lanes 1^3), represent 1/50 of the cell extracts used for coimmu-
noprecipitations. The asterisk indicates the migration of the anti-
body heavy chain.
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Potentially, the suppressive e¡ect of E1B-55K on p53-medi-
ated repression of the survivin promoter might result from a
sequestering of the Sin3A protein by E1B-55K. If the e¡ect of
E1B-55K on p53-repressed survivin promoter activity was due
to an interference with Sin3A, then overexpression of the
Sin3A protein would be predicted to counteract the e¡ect of
E1B-55K. To test this hypothesis, H1299 cells were cotrans-
fected with the survivin reporter construct and plasmids en-
coding p53, E1B-55K and Sin3A proteins. Interestingly, coex-
pression of the Sin3A protein reduced the E1B-55K activating
e¡ect and resulted in partial restoration of the repressor ac-
tivity to p53 (Fig. 4, compare lanes 3 and 5). We have also
observed a similar result by transiently overexpressing the
HDAC1 protein (data not shown).
Collectively, these results suggest that E1B-55K may target
the Sin3 complex to regulate p53-mediated transcriptional re-
pression of the survivin promoter.
3.4. E4orf6 augments the e¡ect of E1B-55K on p53-mediated
repression of the survivin promoter
Like the E1B-55K protein, the adenovirus E4orf6 protein
has been shown to bind to p53 and block its activity as a
transcriptional activator protein [20]. We therefore decided
to test whether the E4orf6 protein also had an e¡ect on
p53-repressed transcription. As shown in Fig. 5A, the
E4orf6 protein, alone, was unable to relieve p53-mediated
repression of the survivin promoter (lanes 6 and 7). However,
in combination with E1B-55K, the E4orf6 protein ampli¢ed
the e¡ect of E1B-55K (lanes 4 and 5). The same experimental
set-up was used to study the e¡ect of E4orf6 on p53-activated
transcription of the cyclin G promoter (Fig. 5B). However,
coexpression of E4orf6, alone or together with E1B-55K, did
not signi¢cantly repress cyclin G promoter activity (lanes 4^
7).
Taken together, these data suggest that E4orf6 strengthens
the e¡ect of E1B-55K on p53-repressed transcription, but
does not have a signi¢cant e¡ect on p53-activated transcrip-
tion, in our assay system.
4. Discussion
Here we show that the Ad2 E1B-55K protein blocks p53
both as a transcriptional activator and as a transcriptional
repressor protein. Interestingly, both e¡ects require that
E1B-55K interacts with the amino-terminal transactivation
domain of p53. However, a closer inspection of the data sug-
gests a small, but potentially important, di¡erence in results.
Thus, E1B-55K binding to p53 appeared to be essential for
E1B-55K to function as an inhibitor of p53 as a transcrip-
tional repressor protein. The mutation in E1B-55K [E1B-
55K(H259A)], which disrupts protein^protein interactions,
was essentially unable to relieve p53 as repressor protein of
both survivin and MAP4 promoter activity (Fig. 2A,C). In
contrast, the same mutant protein was only partially defective
in blocking p53 as a transcriptional activator of the cyclin G
promoter (Fig. 2B). This ¢nding is in line with previous ex-
periments showing that E1B-55K does not simply inactivate
p53 as a transcriptional activator protein by masking the
transactivation domain [21]. Thus, a physical interaction be-
tween E1B-55K and p53 appeared to be most important for
E1B-55K to function as an inhibitor of p53-mediated repres-
sion of transcription.
The activity of p53 as a transcriptional repressor protein
has previously been suggested to result from a recruitment
of histone deacetylases in the Sin3 complex to the promoter
of a repressed gene [7,8]. In addition, we have shown that the
E1B-55K protein interacts with HDAC1 and Sin3A [10].
Therefore, we hypothesized that the blocking activity of
E1B-55K on p53 as a transcriptional repressor protein could
be due to the fact that both proteins might compete for the
binding to the Sin3A protein. Indeed, transient overexpression
of the Sin3A protein partially abrogated the repressive e¡ect
Fig. 4. Sin3A overexpression partially abolishes the e¡ect of E1B-
55K as a suppressor of p53-mediated repression of survivin pro-
moter activity. H1299 cells were transfected with plasmids encoding
the survivin luciferase promoter construct (SpII, 1 Wg), p53(wt) (10
ng), E1B-55K (50 ng) and increasing amounts (100^250 ng) of
Sin3A encoding plasmids. The activity of SpII in the absence of p53
was taken as 100%.
Fig. 5. E4orf6 augments the e¡ect of E1B-55K as a suppressor of
p53-mediated repression of survivin promoter activity. A: H1299
cells were transfected with the survivin luciferase promoter construct
(SpII, 1 Wg), 10 ng of p53, 50 ng of E1B-55K and increasing
amounts (10^50 ng) of E4orf6 encoding plasmids. The activity of
SpII in the absence of p53 was taken as 100%. B: H1299 cells were
transfected with 100 ng of the cyclin G promoter construct and the
same amounts of plasmids encoding p53, E1B-55K and E4orf6 as in
A. The activity of the cyclin G promoter in the presence of p53 was
taken as 100%.
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of E1B-55K on p53-mediated repression of the survivin pro-
moter (Fig. 4).
It is likely that p53 inhibits the survivin promoter in more
ways than by the recruitment of the Sin3 complex. The survi-
vin promoter contains numerous Sp1, putative p53 and E2F1
binding sites [7,22]. In a recent study, Ho¡man and coworkers
have proposed a model, whereby p53-recruited Sin3 complex
generates a chromatin conformation, which will impair E2F1
binding/transactivation of the survivin promoter [7]. Although
an attractive model, the p53 binding to the survivin promoter
has been reported to be controversial and may depend on the
experimental system [11]. It should be noted that we have
been unable to detect binding of p53 to the survivin promoter
in chromatin immunoprecipitation assays (data not shown).
The repressive e¡ect of p53 on the survivin promoter may also
be indirect and dependent on p53 activating synthesis of a
repressor protein [7].
The adenovirus E4orf6 protein has previously been re-
ported to bind p53 and inhibit p53 as a transcriptional acti-
vator protein [20,23]. However, we found that under our ex-
perimental conditions transient E4orf6 expression had no
e¡ect on either p53-repressed or -activated transcription
(Fig. 5A,B). In contrast, our data showed that the E4orf6
protein speci¢cally augmented the opposing e¡ect of E1B-
55K on p53-mediated repression of survivin transcription.
This e¡ect was selective since E4orf6 did not impinge on the
activity of E1B-55K as an inhibitor of p53-mediated activa-
tion of cyclin G transcription (Fig. 5B). Although previous
studies have shown that the E1B-55K/E4orf6 protein complex
causes p53 ubiquitination and degradation [24], it appears
unlikely that this is the major e¡ect seen under our experi-
mental conditions. Thus, if the E1B-55K/E4orf6 complex
acted by degrading the p53 protein one would have expected
to see an e¡ect of E1B-55K and E4orf6 coexpression, not only
on p53-mediated transcriptional repression (Fig. 5A), but also
on p53-mediated transcriptional activation (Fig. 5B). It is
possible that the E1B-55K/E4orf6 complex works in concert
to enhance survivin transcription by an alternative, but un-
known mechanism.
What is the potential physiological signi¢cance of E1B-55K
regulating survivin gene expression? Survivin is a bifunctional
protein that inhibits apoptosis and promotes cell division (re-
viewed in [25]). One possible explanation is that E1B-55K
counteracts p53-induced apoptosis by upregulating expression
of the anti-apoptotic survivin protein. Interestingly, in a mi-
croarray study survivin transcription was shown to be en-
hanced at early times of a wild-type adenovirus infection
(Zhao, Granberg, El¢neh, Pettersson and Svensson, submit-
ted). Furthermore, a recent study shows that the HIV-1 Vpr
protein stimulates transcription from the survivin promoter
[26]. Collectively, these results point toward the possibility
that viral control of survivin gene expression may be a sig-
ni¢cant mechanism contributing to viral inhibition of apopto-
sis.
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